Comparative safety and efficacy of bisphosphonates, denosumab, and parathyroid hormone analogs for osteoporosis following lung transplantation.

January SE, Fester KA, Escamilla JE, Cano M

Pharmacotherapy3 Jul 2025Cited by 1 (Europe PMC)

PMID40605738DOI10.1002/phar.70040PepBankPUB-40605738

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

01HumanNot a test of Abaloparatide (Tymlos) aloneObservational studySafety outcome
In lung transplant recipients, infection incidence was significantly lower with pooled PTH analogs than with denosumab or bisphosphonates, but this did not hold on multivariable modeling.
In plain wordsIn lung transplant recipients, pooled PTH analogs were linked to fewer infections than denosumab or bisphosphonates, but not after adjustment for other factors.
Peptide
Abaloparatide (Tymlos)
Outcome
MixedInfection incidence, unadjusted and multivariable
Study
n: not reported in source
Comparator
denosumab or bisphosphonates
Analysis
Primary
Outcome group
Adverse events · Infection
Source sentences
Summary
Infection incidence was significantly lower in the PTH analog group than the denosumab or bisphosphonate group, but this did not retain significance on multivariable modeling.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-center retrospective study evaluated lung transplant patients treated with the PTH analogs teriparatide or abaloparatide, RANKL inhibitor denosumab, or bisphosphonates.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4060573801
02HumanNot a test of Abaloparatide (Tymlos) aloneObservational studySafety outcome
In lung transplant recipients, pooled PTH analogs were linked to fewer treated rejection episodes than bisphosphonates, which began earlier after transplantation.
In plain wordsIn lung transplant recipients, pooled PTH analogs were linked to fewer treated rejections than bisphosphonates, which began earlier after transplantation.
Peptide
Abaloparatide (Tymlos)
Outcome
DecreaseTreated allograft rejection episodes
Study
n: not reported in source
Comparator
bisphosphonates
Analysis
Secondary
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
Treated allograft rejection episodes were higher in those with bisphosphonate use, significantly so when compared to PTH analog patients, but patients treated with bisphosphonates were also started on therapy earlier after their transplant when rejection risk is higher.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-center retrospective study evaluated lung transplant patients treated with the PTH analogs teriparatide or abaloparatide, RANKL inhibitor denosumab, or bisphosphonates.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4060573805
03HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyEfficacy outcome
In lung transplant recipients, pooled PTH analogs increased lumbar spine BMD from baseline, as did the other medication groups.
In plain wordsIn lung transplant recipients, pooled PTH analogs were linked to increased lower spine bone density from baseline, as were other medication groups.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseLumbar spine BMD
Study
n: not reported in source
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
All agents were effective at increasing BMD of the lumbar spine, none improved BMD of the femoral neck, and only PTH analogs significantly improved hip BMD.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-center retrospective study evaluated lung transplant patients treated with the PTH analogs teriparatide or abaloparatide, RANKL inhibitor denosumab, or bisphosphonates.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4060573806
04HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyEfficacy outcome
In lung transplant recipients, pooled PTH analogs did not improve femoral neck BMD from baseline, nor did the other medication groups.
In plain wordsIn lung transplant recipients, pooled PTH analogs were not linked to improved femoral neck bone density from baseline, nor were other medication groups.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeFemoral neck BMD
Study
n: not reported in source
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
All agents were effective at increasing BMD of the lumbar spine, none improved BMD of the femoral neck, and only PTH analogs significantly improved hip BMD.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-center retrospective study evaluated lung transplant patients treated with the PTH analogs teriparatide or abaloparatide, RANKL inhibitor denosumab, or bisphosphonates.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4060573807
05HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyEfficacy outcome
In lung transplant recipients, pooled PTH analogs significantly increased hip BMD.
In plain wordsIn lung transplant recipients, pooled PTH analogs were linked to increased hip bone density from baseline.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseHip BMD
Study
n: not reported in source
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
All agents were effective at increasing BMD of the lumbar spine, none improved BMD of the femoral neck, and only PTH analogs significantly improved hip BMD.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-center retrospective study evaluated lung transplant patients treated with the PTH analogs teriparatide or abaloparatide, RANKL inhibitor denosumab, or bisphosphonates.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4060573808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.